Table 1.
Clinical and biological characteristics of the cohort of diffuse large B-cell lymphoma patients
| treatment | number | gender | age | stage | IPI1 | RT6m2 | TTF3 | PME/NTP4 |
|---|---|---|---|---|---|---|---|---|
| CHOP5: | 1 | F | 68 | II | 1 | CR | +23.0 | 2.16 |
| 2 | F | 49 | I | 2 | CR | 18.0 | 0.84 | |
| 3 | F | 48 | II | 0 | CR | +186.0 | 1.52 | |
| 4 | M | 29 | IV | 1 | PR | 9.8 | 1.85 | |
| 5 | M | 59 | III | 1 | PR | 8.0 | 2.83 | |
| 6 | F | 68 | IV | 2 | CR | +165.7 | 1.32 | |
| 7 | M | 53 | II | 1 | CR | +157.1 | 1.92 | |
| 8 | F | 51 | III | 2 | CR | +161.8 | 1.88 | |
| 9 | M | 77 | II | 3 | PR | +4.7 | 1.97 | |
| 10 | F | 74 | IV | 3 | CR | 140.0 | 1.32 | |
| 11 | M | 63 | III | 1 | CR | 76.4 | 1.51 | |
| 12 | M | 53 | II | 1 | CR | 108.1 | 1.39 | |
| ProMACE-CytaBOM6: | 13 | F | 19 | III | 0 | CR | +100.0 | 1.43 |
| CHOP plus ICE7: | 14 | F | 47 | IV | 4 | PR | 5.2 | 2.86 |
| CNOP8: | 15 | M | 48 | IV | 2 | CR | 58.0 | 0.86 |
| PMitCEBO9: | 16 | M | 85 | III | 3 | PR | 7.1 | 2.59 |
|
CHOP-like (not-specified) |
17 | M | 70 | III | 4 | PR | 10.5 | 2.50 |
| 18 | F | 66 | IV | 2 | PR | 6.1 | 2.65 | |
| 19 | M | 65 | I | 3 | CR | +30.6 | 1.46 | |
| 20 | M | 58 | III | 2 | CR | +10.8 | 0.89 |
1
IPI: International Prognostic Index
2
TR6m: treatment response at 6 months (CR: complete response, PR: partial response)
3
TTF: time to treatment failure (+ denotes censored)
4
PME/NTP: pretreatment tumor PME/NTP value
5
CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone
6
ProMACE-CytaBOM : CHOP plus etoposide, cytarabine, bleomycin, methotrexate, and leucovorin
7
ICE : ifosfamide, carboplatin, etoposide
8
CNOP : cyclophosphamide, mitoxantrone, vincristine, and prednisone
9
PMitCEBO: CNOP plus etoposide and bleomycin